NCT00346008

Brief Summary

RATIONALE: Studying the genes expressed in samples of blood from patients with cancer and their family members may help doctors identify biomarkers related to cancer. PURPOSE: This clinical trial is studying genes to identify melanoma in patients in Iceland and their family members.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2005

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2005

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

June 27, 2006

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 29, 2006

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2008

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2009

Completed
Last Updated

May 30, 2013

Status Verified

December 1, 2008

Enrollment Period

3.2 years

First QC Date

June 27, 2006

Last Update Submit

May 29, 2013

Conditions

Melanoma (Skin)

Keywords

melanomarecurrent melanomastage I melanomastage II melanomastage III melanomastage IV melanoma

Outcome Measures

Primary Outcomes (3)

  • Feasibility to identify melanoma

  • Feasibility to detect mutation

  • Ability to create datasets

Interventions

mutation analysisGENETIC
high performance liquid chromatographyOTHER
laboratory biomarker analysisOTHER
questionnaire administrationOTHER

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
DISEASE CHARACTERISTICS: * Patients diagnosed with melanoma and selected family members are eligible to participate * Must live in Iceland PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (1)

Iceland Genomics Corporation

Reykjavik, 105, Iceland

Location

MeSH Terms

Conditions

Melanoma

Interventions

Chromatography, High Pressure Liquid

Condition Hierarchy (Ancestors)

Neuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Nerve TissueNevi and MelanomasSkin NeoplasmsNeoplasms by SiteSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Chromatography, LiquidChromatographyChemistry Techniques, AnalyticalInvestigative Techniques

Study Officials

  • Alisa Goldstein, PhD

    National Cancer Institute (NCI)

    STUDY CHAIR

Study Design

Study Type
observational
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

June 27, 2006

First Posted

June 29, 2006

Study Start

October 1, 2005

Primary Completion

December 1, 2008

Study Completion

February 1, 2009

Last Updated

May 30, 2013

Record last verified: 2008-12

Locations

IC(1)